Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06993610 · ClinicalTrials.gov registry record · Phase 2
Tibulizumab Skin Healing and Inflammation Evaluation for Lasting Defense
A Phase 2 study of Hidradenitis Suppurativa (HS), sponsored by Zura Bio.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 225
- Enrollment target
- 20
- Study locations
NCT06993610: Recruiting Phase 2 study of Hidradenitis Suppurativa (HS), sponsored by Zura Bio.
NCT06993610 is a Phase 2 study of Hidradenitis Suppurativa (HS) that is actively recruiting participants, run by Zura Bio. The registered enrollment target is 225 participants, above the 162-participant average among 12 other Hidradenitis Suppurativa (HS) trials with a reported enrollment target (39% higher). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06993610, a Phase 2 study of Hidradenitis Suppurativa (HS), is actively recruiting participants, sponsored by Zura Bio.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 225 participants
- Enrollment target
- 20
- Study locations
Study Summary
The study is a Phase 2, multi-center, randomized, double-blind, placebo-controlled study to evaluate the effects of tibulizumab over 16 weeks (Period 1) in adults with hidradenitis suppurativa, followed by a 16-week open-label extension period in which all participants will receive tibulizumab (Period 2)
Primary Outcome
AN count is calculated based on the sum of the abscesses and inflammatory nodules across different anatomical areas
Conditions Studied
Interventions
- OTHER Placebo
- BIOLOGICAL Tibulizumab Dose A
- BIOLOGICAL Tibulizumab Dose B
Study Locations (20)
California
- First OC Dermatology Research, Inc. - Irvine
- Wallace Medical Group, Inc. - Los Angeles
- Northridge Clinical Trials - Northridge
- NorCal Clinical Research - Rocklin
Indiana
- Indiana University School of Medicine - Indianapolis
- The Indiana Clinical Trials Center - Plainfield
Kentucky
- Equity Medical LLC (Kentucky) - Bowling Green
- DS Research of Kentucky, LLC - Louisville
Louisiana
- DelRicht LLC - Baton Rouge
- Clinical Trials Management, LLC - Metairie
New York
- Equity Medical - New York
- OptiSkin Medical - New York
Ohio
- Optima Research - Boardman
- ClinOhio Research Services - Columbus
Arizona
- Medical Dermatology Specialists (Phoenix) - Phoenix
Florida
- Florida Academic Dermatology Center - Coral Gables
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 225 participants |
| Start Date | 2025-05-16 |
| Est. Completion | 2027-04 |
| Phase | Phase 2 |
What NCT06993610 shows while recruiting
NCT06993610 is an interventional study that assigns participants to a tested intervention. The registered 225 participants enrollment target is mid-sized for trials with a published cap, above the 162-participant average among 12 other Hidradenitis Suppurativa (HS) trials with a reported enrollment target (39% higher).
The record links to 1 condition, with Hidradenitis Suppurativa (HS) appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT06993610 names 20 study sites across 12 states, led by California, Indiana, Kentucky.
Frequently Asked Questions
What is clinical trial NCT06993610 about?
NCT06993610 is a clinical study titled "Tibulizumab Skin Healing and Inflammation Evaluation for Lasting Defense". The study is a Phase 2, multi-center, randomized, double-blind, placebo-controlled study to evaluate the effects of tibulizumab over 16 weeks (Period 1) in adults with hidradenitis suppurativa, followed by a 16-week open-label extension period in which all participants will receive tibulizumab (Peri...
What is the current status of trial NCT06993610?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 225 participants. The study started on 2025-05-16. Estimated completion is 2027-04.
What conditions does trial NCT06993610 study?
This clinical trial studies the following conditions: Hidradenitis Suppurativa (HS).
What interventions are being tested in trial NCT06993610?
The interventions under investigation include: Placebo (OTHER), Tibulizumab Dose A (BIOLOGICAL), Tibulizumab Dose B (BIOLOGICAL).
Who is sponsoring clinical trial NCT06993610?
This trial is sponsored by Zura Bio, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06993610 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Georgia, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hidradenitis Suppurativa (HS)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06993610's enrollment target sits among peer trials
225 3rd of 12 higher than 10 of 12 other Hidradenitis Suppurativa (HS) trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hidradenitis Suppurativa (HS) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Assess NAV-240 in Adult Participants With Hidradenitis Suppurativa
RECRUITING · Phase 2
-
The Safety and Efficacy of Roflumilast Foam in HS
RECRUITING · Phase 2
-
A Study Evaluating BFB759 in Moderate to Severe Hidradenitis Suppurativa
RECRUITING · Phase 2
-
Pharmacokinetics, Safety, and Efficacy of Povorcitinib in Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa
RECRUITING · Phase 2
-
Hidradenitis Suppurativa Wound Care
COMPLETED · Phase 2
-
Participants with Mild to Moderate Hidradenitis Suppurativa Will Receive EVO101 a Topical Cream 0.1%
RECRUITING · Early Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03955445 · 225 participants · Phase 3
Long-term Efficacy, Safety and Tolerability of Iptacopan in C3G or IC-MPGN
- NCT04054310 · 225 participants · NA
Non-Invasive Quantification of Liver Health in NASH (N-QUAN)
- NCT04480554 · 225 participants · Phase 2
Anti-retroviral Therapy, Medications for Opioid Use Disorder, Opioids and HIV Infection - Study 1
- NCT04888104 · 225 participants
Prospective, Multicenter, Case-Control Analysis of the VersaTie Posterior Fixation System to Prevent Proximal Junctional Failure in Long Posterior Spinal Fusion Constructs for Adult Patients
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI